- Brean Capital raises it price target for Zogenix (NASDAQ:ZGNX) to $28 (58% upside), citing the potential of its two lead product candidates, ZX008 for Dravet syndrome and Relday (risperidone) for schizophrenia.
- Phase 3 trials for Orphan Drug-tagged ZX008 are set to begin in Q3 in the U.S. and Europe. Results from the Relday Multi-Dose study are also expected in Q3.
- Zogenix sold its Zohydro ER business to Pernix Therapeutics (NYSEMKT:PTX) for up to ~$284M in March.
- Previously: Zogenix sells Zohydro business to Pernix Therapeutics for up to $384M (March 10)